Zanubrutinib
- Generic Name
- Zanubrutinib
- Brand Names
- Brukinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O3
- CAS Number
- 1691249-45-2
- Unique Ingredient Identifier
- AG9MHG098Z
- Background
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
- Indication
Zanubrutinib is indicated for the treatment of:
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
- Associated Therapies
- -
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Zhang Lei, MD
- Target Recruit Count
- 10
- Registration Number
- NCT05199909
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
🇨🇳Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- Conditions
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05168930
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸South Shore Hospital, South Weymouth, Massachusetts, United States
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05117814
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 750
- Registration Number
- NCT05100862
- Locations
- 🇺🇸
Ucsf Fresno University of California San Francisco Fresno, Fresno, California, United States
🇺🇸Kaiser Permanente Southern California, Irvine, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 66
- Registration Number
- NCT05068440
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04899570
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04899453
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Yazeed Sawalha
- Target Recruit Count
- 24
- Registration Number
- NCT04850495
- Locations
- 🇺🇸
MUSC, Charleston, South Carolina, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-09-16
- Target Recruit Count
- 78
- Registration Number
- NCT04835870
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04743687
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.